Back to News
Market Impact: 0.45
Nano Cap Lisata Therapeutics Bolsters Cardioendocrine Pipeline Strategy
Source: benzinga.com
M&A & RestructuringPrivate Markets & VentureHealthcare & Biotech
Lisata Therapeutics acquired clinical-stage biotech Marea Therapeutics and completed an oversubscribed $225 million private-placement financing. The transaction materially strengthens Lisata's capital base and expands its clinical-stage biotechnology platform, with likely positive implications for the company's development pipeline.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.60
Ticker Sentiment
LSTA0.85
More News
- Amgen (AMGN) Bets on MariTide to Crack $120 Billion Obesity Market
- Apollo launches $11 billion private credit platform, backed by Abu Dhabi
- Wells Fargo raises Abbvie stock price target to $340 on pipeline
- Mizuho raises Dominion Energy stock price target to $68 on earnings beat
- Citizens reiterates Ondas Holdings stock rating on IonStrike updates
- German Firms Mahle, Schott Said to Seek Banks for India IPOs